However, it quickly became clear in the discussions that there is still a gap between ambition and reality. Representatives from industry and politics pointed above all to regulatory hurdles and a lack of growth capital as the main factors slowing things down. In dialogue with the EU Commission and industry representatives, it became clear that while Europe is well positioned in terms of early-stage financing, it lags behind when it comes to scaling. Many innovations leave the continent before they develop added value. Initiatives such as the Deutschlandfonds are intended to counteract this, but concrete relief has so far remained vague. The industrial perspective was also differentiated. Successful segments such as enzymes and amino acids stand alongside areas that are still waiting for their breakthrough. At the same time, the pressure on contract manufacturers is growing due to complex regulation, rising costs and a shortage of skilled labour. With more than 30 specialised formats and numerous pitches, the event nevertheless demonstrated the full dynamism of the industry. For Leipzig, the meeting is a signal of its own ambition to establish itself as a visible hub for European biotechnology and to catch up further in the competition for talent, capital and innovation.
News of "BIO Deutschland e.V." from 24.04.2026